ImmunoPrecise Antibodies (ImmunoPrecise Antibodies) Gross-Profit-to-Asset % : 16.75% (As of Jan. 2024)

ImmunoPrecise Antibodies Gross-Profit-to-Asset % Chart

ImmunoPrecise Antibodies Annual Data
	Trend	Dec13	Dec14	Dec15	Apr17	Apr18	Apr19	Apr20	Apr21	Apr22	Apr23
Gross-Profit-to-Asset %		Get a 7-Day Free Trial					19.51	28.11	25.30	13.62	13.01

ImmunoPrecise Antibodies Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															14.49	16.64	14.63	15.23	16.75

Competitive Comparison of ImmunoPrecise Antibodies's Gross-Profit-to-Asset %

For the Biotechnology subindustry, ImmunoPrecise Antibodies's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmunoPrecise Antibodies's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmunoPrecise Antibodies's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where ImmunoPrecise Antibodies's Gross-Profit-to-Asset % falls into.

ImmunoPrecise Antibodies Gross-Profit-to-Asset % Calculation

ImmunoPrecise Antibodies's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Apr. 2023 is calculated as:

ImmunoPrecise Antibodies's annualized Gross-Profit-to-Asset % for the quarter that ended in Jan. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Jan. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

ImmunoPrecise Antibodies Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of ImmunoPrecise Antibodies's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmunoPrecise Antibodies (ImmunoPrecise Antibodies) Business Description